|31 October 2016|
USA
A venture capitalist firm dedicated to supporting industries transforming our world has just raised $616 million dollars for the next generation of biotech pioneers.
The fund from Third Rock Venture will back innovative biotech startups and build on the company’s “strategy of creating innovative healthcare companies to make a meaningful difference in the lives of patients and their families”.
“We appreciate the ongoing support from all the investors participating in Fund IV. Over the years, we have continued to build a leading investor base that is supportive of our unique model – a hands-on, team-based approach of discovering, launching and building great companies based on bold ideas that meet at the intersection of science, strategy, business and medicine,” said Robert Tepper, M.D., partner at Third Rock. “Our investment has always been shaped by the ongoing tremendous innovation in science and medicine. We aim to be both the preferred partner to scientific innovators from academia, and the preferred provider of innovative programs in important disease areas to address the bio-pharma industry’s pipeline needs.”
